An effort by Sanofi to transform its dengue vaccine into a blockbuster product has, instead, turned into a scandal for the drug maker and a public health crisis in the Philippines, where the government is investigating why the vaccine was so widely adopted, despite studies suggesting its use would not be appropriate for everyone.

The issue erupted last week when the company disclosed that a new analysis found its Dengvaxia vaccine could actually make future cases of the mosquito-borne virus more severe in people who were not previously infected. And so, Sanofi changed the product labeling to limit use to people who were not exposed to Dengue in the past.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy